Necrotizing vasculitis

This study tests whether the Butantan-Dengue vaccine is safe and works well in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable on low or no immune-suppressing drugs. Participants receive one vaccine dose and are monitored f…

This Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive in…

Researchers are testing whether regularly checking a marker called Gd-IgA1 can help doctors adjust treatment for IgA nephropathy, a kidney disease. Adults with biopsy-confirmed IgA nephropathy or IgA vasculitis-associated nephritis receive Nefecon or telitacicept. Half have Gd-Ig…

This phase 2 trial is testing whether a new drug called obinutuzumab beta, combined with a short course of steroids, can help people with newly diagnosed ANCA-associated glomerulonephritis—a rare autoimmune disease that causes kidney inflammation and damage. The study will enroll…

Researchers are studying how well benralizumab works in adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that inflames blood vessels and can affect the lungs, nerves, and sinuses. The study follows about 100 patients at European referral centers wh…

This trial tests an investigational cell therapy called FT839 in people with active autoimmune diseases, including ANCA-associated vasculitis, inflammatory myositis, rheumatoid arthritis, lupus, and systemic sclerosis. Participants receive FT839 as two intravenous infusions, some…

This study tests whether adding TAVNEOS to standard treatment helps control ear, nose, and throat symptoms in people with granulomatosis with polyangiitis (GPA). About 30 adults with active ENT disease will receive either TAVNEOS or a placebo for 52 weeks. The goal is to see if m…

This study tests three standard medications—colchicine, dapsone, and azathioprine—in 90 people with isolated skin vasculitis (inflammation of small or medium blood vessels in the skin). Participants are randomly assigned to one of the drugs, and doctors track how well the skin re…

This study gives ongoing access to benralizumab (Fasenra) for people with asthma, eosinophilic granulomatosis with polyangiitis (EGPA), or hypereosinophilic syndrome (HES) who completed a prior benralizumab trial and still benefit from the drug. About 230 participants will receiv…

This study is checking the long-term safety of a drug called avacopan for people with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. About 300 adults who need treatment for a new diagnosis or flare-up will take avacopan or a placebo. The…

This Phase 2 trial tests whether adding ALE.F02 to standard therapy can protect kidney function in people with ANCA-associated vasculitis, an autoimmune disease that attacks small blood vessels, often damaging the kidneys. About 80 participants will receive either a low, high, or…

This Phase 3 trial is testing whether adding BDB-001 to standard treatments (cyclophosphamide, azathioprine, rituximab, or prednisone) helps more people with ANCA-associated vasculitis achieve remission. The study plans to enroll 300 adults with active GPA or MPA. Participants wi…

This study tests a new drug, BBD-1, against standard steroids for IgA vasculitis, a disease that causes purple spots on the skin, joint pain, and can damage the kidneys. The trial will enroll 30 adults with confirmed IgA vasculitis. The goal is to see if BBD-1 can clear skin spot…

This study tests a new treatment called NKX019 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, and vasculitis. NKX019 uses specially engineered immune cells to target and calm overactive B cells that cause the disease. The goal is to see if it i…

This early study tests whether a liquid form of the drug avacopan can be safely given through a feeding tube to critically ill patients with ANCA vasculitis who have severe lung bleeding and need a ventilator. The main goal is to measure how the drug levels change in the blood ov…

This early-stage study tests a new treatment called RD06-05, a universal CAR-T cell therapy, in up to 84 adults with autoimmune diseases like lupus, vasculitis, and scleroderma. The therapy targets and removes faulty immune cells to help control the disease. The main goal is to c…

This study tests a drug called ravulizumab in children aged 2 to 18 with a kidney disease called IgA nephropathy. The goal is to see if the drug can reduce protein in the urine, a sign of kidney damage. Participants will receive the drug through an IV and be monitored for safety …

This early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The stu…

This early study tests a new treatment called CD19/BCMA CAR-T for people with severe autoimmune diseases like lupus and Sjögren's syndrome that haven't improved with standard care. The treatment involves taking a patient's own immune cells, modifying them to target specific immun…

This study looks at whether people with rheumatic diseases (like rheumatoid arthritis or lupus) can safely stop their immunosuppressant medications for a shorter time before elective shoulder replacement surgery. The goal is to see if this approach lowers the chance of disease fl…

This early-stage trial tests a new therapy called FKC289, which uses a patient's own immune cells engineered to target two proteins (BCMA and CD19) on cells that drive autoimmune attacks. The goal is to see if it is safe and can help control kidney diseases like lupus nephritis a…

This trial investigates whether pioglitazone, a drug used for diabetes, can help protect the kidneys in people with ANCA-associated vasculitis—a rare autoimmune disease that causes inflammation of blood vessels, often damaging the kidneys. Participants receive either pioglitazone…

This early-phase trial is testing a new drug called MTS109, made with mRNA technology, for people with moderate to severe autoimmune diseases like lupus and scleroderma. Fifteen participants will receive several injections over a month to see if it is safe and tolerable. The goal…

This Phase 2 study tests atacicept, a drug that may reduce immune system attacks on the kidneys. About 250 adults with various autoimmune kidney diseases (like IgA nephropathy or membranous nephropathy) will receive weekly injections. Researchers will check safety and measure cha…

This early-phase trial tests a new treatment called KN5501, which uses specially engineered immune cells (CAR NK cells) to target and destroy harmful B cells in people with relapsed or refractory immune nephropathy, a kidney disease caused by the immune system attacking the kidne…

This study tests a new drug called tarperprumig in 75 adults with ANCA-associated vasculitis, a rare disease where the immune system attacks blood vessels. The goal is to see if the drug is safe and can help control the disease by reducing inflammation. Participants will receive …

This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…

This early-stage study is testing a new cell therapy called FT819 for people with severe autoimmune diseases like lupus, vasculitis, and scleroderma. The treatment involves giving specially engineered immune cells along with chemotherapy drugs. The main goal is to see if it's saf…

This study tests a new treatment called QT-219CX, which uses specially engineered immune cells (CAR-T cells) to target and calm the overactive immune system in people with autoimmune diseases like lupus, kidney disease, and scleroderma. The treatment is given as a one-time infusi…

This study tests an oral drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants must have a certain level of kidney function to join.

This early study is testing a new treatment called CD19 CAR-T therapy for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard medications. The therapy involves taking a patient's own immune cells, reprogramming them to target and …

This phase 3 trial is for people with granulomatosis with polyangiitis (GPA), a rare autoimmune disease causing blood vessel inflammation, who did not get better with standard treatments. It compares three salvage therapies: rituximab plus another drug, tocilizumab, or tofacitini…

This early-phase trial is testing a new type of cell therapy called QT-219C, which uses donor-derived CAR-T cells to target and destroy faulty immune cells in people with severe autoimmune diseases like lupus, nephrotic syndrome, and vasculitis. The study will enroll 15 participa…

This early-phase trial is testing a personalized cell therapy called CAR-T, designed to target and destroy faulty immune cells in people with active autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. Up to 20 participants will receive the treatment after a short…

This study tests a drug called obinutuzumab in 33 adults with a relapsing form of granulomatosis with polyangiitis (GPA, formerly Wegener's). The goal is to see if the drug can stop disease activity and turn off the related antibody. Participants will be followed for 6 months to …

This early-stage study tests a new cell therapy called YTS109 in 18 adults aged 18-65 with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and…

This early-stage trial is testing a new treatment called YTS109 for people with severe autoimmune diseases like lupus and Sjogren's syndrome that have come back or not responded to standard care. About 18 adults will receive a single infusion of these specially engineered immune …

This early-stage study tests a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of the cells, and researchers monitor safety and how…

This early-stage study tests a new cell treatment called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and scleroderma. Participants receive a single infusion of these specially designed cells. The main goal is to check if the treatment is safe, and also t…

This early-phase study tests a new type of CAR-T cell therapy (called KN3601) for people with severe autoimmune diseases like lupus, scleroderma, Sjögren's syndrome, rheumatoid arthritis, and vasculitis that haven't responded to standard treatments. The therapy uses specially eng…

This early-phase study tests a new treatment called TI-0032-III for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard care. The treatment uses a special injection to create CAR-T cells inside the body, which then target and dest…

This early-phase study tests a new treatment called anti-CD19/BCMA universal CAR T cells (KN3601) for people with relapsed or refractory immune-mediated kidney disease. The therapy involves collecting a patient's immune cells, engineering them to target and destroy harmful B cell…

This early-stage study is testing a universal donor CAR T-cell therapy that targets two proteins (CD19 and BCMA) on immune cells that drive autoimmune diseases. The goal is to see if it is safe and can help control conditions like lupus, kidney disease, and vasculitis. About 15 p…

This early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…

This phase 3 trial is testing whether a 4-week low-dose steroid regimen, given alongside standard drugs like rituximab or cyclophosphamide, is safer and as effective as the usual longer steroid treatment for ANCA vasculitis with severe kidney problems. The study will enroll 36 pe…

This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target …

This study tests whether adding finerenone to standard blood pressure medication (ACEI/ARB) can better reduce protein in the urine of children with Henoch-Schönlein purpura nephritis and mild proteinuria. About 116 children aged 3 to 17 will take either finerenone plus ACEI/ARB o…

This study tests a new treatment using specially engineered immune cells (CAR-NK) from cord blood for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis that haven't responded to standard therapies. The goal is to see if it's safe and can control the d…

This early-phase trial is testing a personalized immune cell therapy called CD19 CAR-T in 15 people with severe autoimmune diseases like lupus and scleroderma that haven't responded to standard treatments. The therapy aims to temporarily deplete certain immune cells to calm the o…

This early-phase study is testing a new cell therapy called LUCAR-DKS1 in 36 adults with relapsed or refractory autoimmune diseases like lupus. Participants receive their own modified NK cells after a short chemotherapy prep. The main goals are to check safety, find the right dos…

This study tests a new drug, SHR-1703, for people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that causes inflammation in blood vessels. The trial will include 166 adults who have not responded well to standard treatments. The goal is to see if SHR-1…

This early-stage study tests a new treatment for people with severe autoimmune diseases like lupus and scleroderma that haven't improved with standard therapies. The treatment uses specially engineered immune cells (CAR T-cells) from a healthy donor to target and potentially rese…

This study looks at whether continuing a low dose of prednisone (5 mg/day) for an extra 12 months can help people with a type of blood vessel inflammation called ANCA-associated vasculitis stay in remission. About 146 adults who are already in remission and receiving rituximab wi…

This study looks at whether a protein in the blood, called I-FABP, can tell doctors if a child's IgA vasculitis is affecting their stomach or intestines. Researchers will take blood samples from 100 children at diagnosis and again 2-4 weeks later. If I-FABP levels are linked to g…

This study is testing a new type of PET scan tracer (68Ga-FAPI) to see if it can better detect lung and kidney problems in people with ANCA-associated vasculitis, a rare autoimmune disease. The tracer targets specific cells linked to tissue scarring. Researchers will enroll 30 ad…

This study is testing a new blood-based test that aims to predict which medication will work best for each person with rheumatic diseases like rheumatoid arthritis or lupus. Researchers will take a blood sample and analyze immune cells to create a personalized treatment profile. …

This study follows 700 people with eosinophilic granulomatosis with polyangiitis (EGPA), a rare immune disorder causing asthma, high eosinophil levels, and blood vessel inflammation. Researchers aim to discover biological markers that can measure disease activity and predict trea…

This study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…

This study follows up to 4,000 people with vasculitis (a group of diseases that cause blood vessel inflammation) and healthy volunteers over many years. Researchers collect blood, urine, imaging, and genetic samples to learn how the disease develops and changes. The goal is to fi…

This study investigates how changes in kidney cell metabolism relate to the rate of kidney function decline in people with ANCA vasculitis and other kidney diseases. Researchers will analyze kidney biopsy samples and blood/urine tests from 146 participants over one year. The goal…

This study is collecting blood, urine, and fecal samples from 100 people with ANCA-associated vasculitis, a rare autoimmune disease. Researchers will follow participants for up to 5 years, tracking relapses and complications. The goal is to identify factors that predict disease f…

This study looks at how ANCA-associated vasculitis affects the eyes. Researchers will use a special imaging test called OCT angiography to examine blood vessels in the eyes of 70 participants. The goal is to better understand and detect eye involvement early, which could help pre…

This study aims to learn how well heart scans (MRI, ultrasound, PET) can detect and predict outcomes in people with suspected or known inflammatory heart diseases. Researchers will follow 5,000 adults for one year to see how often heart involvement is confirmed and how it affects…

This study is testing whether a special full-body PET scan can more accurately detect active ANCA-associated vasculitis (AAV) and predict long-term heart disease risk. Researchers will scan up to 120 participants (some with active AAV, some healthy) using three different tracers …

This study tracks the pregnancy experiences of women with vasculitis, a group of rare diseases causing blood vessel inflammation. Researchers will use online surveys to understand how vasculitis affects pregnancy and what outcomes occur. The goal is to gather information to help …

This study collects tissue samples from 1,000 people with various forms of vasculitis, a group of rare inflammatory blood vessel diseases. Researchers will analyze the samples alongside clinical data to identify genes that increase risk and to spark new ideas for diagnosis and tr…

This study looks at skin samples from 50 people with different types of vasculitis, a condition where blood vessels become inflamed. Researchers want to understand how the disease affects the skin at a molecular level. Participants must have an active skin rash related to their v…

This study collects DNA samples and medical information from 1,000 people with various forms of vasculitis (blood vessel inflammation). Researchers will analyze the data to identify genes that increase the risk of developing these severe diseases. The goal is to better understand…

This study looks at blood and kidney tissue from 150 adults with IgA nephropathy or related kidney diseases. Researchers want to find unique patterns in immune cells that cause kidney damage. The goal is to develop a blood test that could diagnose the disease without a painful ki…

This study collects medical data from 60 adults diagnosed with either EGPA or HES, two rare conditions that cause high levels of a type of white blood cell. Researchers will use artificial intelligence to find patterns that help doctors tell the diseases apart and predict how pat…

This study is following 670 adults with vasculitis, a rare blood vessel disease, for up to 5 years. Researchers will collect medical data and blood samples to see how the disease starts, how it is treated, and what long-term problems may arise. No new treatments are being tested—…